07:00 , Apr 4, 2013 |  BC Innovations  |  Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylases,1 a not-so-well-understood subset of the target family that has been...
07:00 , Apr 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Histone deacetylase 4 (HDAC4) A study in mice suggests blocking the...
07:00 , Jun 2, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Histone deacetylase 4 (HDAC4); HDAC5; HDAC7 A study in mice suggests...
07:00 , Oct 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular atrophy Histone deacetylase 4 (HDAC4); HDAC5 Studies in mice suggest that inhibiting HDAC4 or HDAC5...
07:00 , Oct 21, 2010 |  BC Innovations  |  Targets & Mechanisms

Unnerving atrophy

A team at The University of Texas Southwestern Medical Center at Dallas has shown that deletion of class IIa histone deacetylases prevents muscle atrophy after nerve damage.1 The result suggests that inhibitors of these molecules...
08:00 , Feb 1, 2010 |  BioCentury  |  Emerging Company Profile

Acetylon: Homing in on HDAC6

Acetylon Pharmaceuticals Inc. hopes that by targeting an isoform of histone deacetylase that operates only in diseased cells, its cancer compounds will produce fewer side effects than less specific HDAC inhibitors. The company expects to...
08:00 , Jan 7, 2010 |  BC Innovations  |  Targets & Mechanisms

Targeting miRNAs in ALS

A team from The University of Texas Southwestern Medical Center at Dallas has identified a muscle-specific microRNA-miR-206-that plays a role in the progression of amyotrophic lateral sclerosis.1 The results suggest that muscle cells could be...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease...
08:00 , Jan 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease ...
08:00 , Nov 13, 2008 |  BC Innovations  |  Targets & Mechanisms

MELOE target for melanoma

Despite the identification of an increasing number of melanoma-specific antigens, including MAGE-1, Melan-A and tyrosinase,1 response rates for melanoma immunotherapy still hover at only 5-10%,2 due in part to the heterogeneity of the melanoma cells...